Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

First-in-Class YAP/TEAD Inhibitor Demonstrates Early Efficacy Targeting Hippo Pathway

January 11th 2024

Investigators hope that first-in-class agents will combat dysfunction of the Hippo pathway by inhibiting the transcription function of TEAD-YAP.function of TEAD-YAP.

Adagrasib Approved in Europe for Pretreated KRAS G12C+ Advanced NSCLC

January 10th 2024

The European Commission has granted conditional marketing authorization to adagrasib for patients with KRAS G12C+ advanced non–small cell lung cancer.

Practical Toxicity Management Awareness With FGFR Inhibitors Improves Real-World Patient Outcomes

January 8th 2024

Vivek Subbiah, MD, emphasizes the need for improved guidance on practical toxicity management for various FGFR-altered malignancies, highlights best practices for monitoring and managing the most common on-target toxicities associated with FGFR inhibitors, and discusses the key implications of this review for those utilizing FGFR inhibitors.

Optimal Personalization of Therapy In TNBC Necessitates Consistent Biomarker Identification

January 7th 2024

Pooja Advani, MBBS, MD, details the encouraging activity of antibody-drug conjugates in triple-negative breast cancer, the importance of utilizing next-generation sequencing to inform treatment selection after progression on CDK4/6 inhibitors in this disease setting, and more.

Dr Ip on the Importance of NGS Testing in Hematologic Malignancies

January 5th 2024

Andrew Ip, MD, discusses findings from a study on the use of next-generation sequencing of flow cytometry CD markers and machine learning as a replacement to flow cytometry analysis for the diagnosis of hematologic neoplasms.

Assessing the Promise of AI in Oncology: Looking to the Future

December 25th 2023

In this final episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss a roadmap of artificial intelligence (AI) advances in the next 5 to 10 years.

Assessing the Promise of AI in Oncology: Matching Patients With Clinical Trials

December 18th 2023

In this eighth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, explain how artificial intelligence tools are being developed to match the right patient to the right drug on the right clinical trial.

Repotrectinib May Serve as a New Standard of Care Across Treatment Lines in ROS1+ NSCLC

December 17th 2023

Alexander Drilon, MD, highlights how the approval of repotrectinib addresses the need for improved therapies for patients who have progressed on a previous TKI and delves into notable neurologic toxicities seen with the agent.

Revumenib Elicits High Response Rate in R/R KMT2A-Rearranged Acute Leukemia

December 12th 2023

Revumenib demonstrated clinically meaningful activity, including high response and minimal residual disease negativity rates, in heavily pretreated patients with KMT2A-rearranged acute leukemia.

Assessing the Promise of AI in Oncology: Improving Patient Interactions and Experience

December 11th 2023

In this seventh episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss how artificial intelligence tools may be utilized to improve wait time for treatment, to provide more time for provider-patient interactions, and more.

Inavolisib Plus Palbociclib and Fulvestrant Improves PFS in PIK3CA-Mutated HR+ Breast Cancer

December 7th 2023

The addition of inavolisib to palbociclib and fulvestrant improved progression-free survival vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer.

Reviewing Best Practices in the Surgical Management of Breast Cancer: Post-Surgery Outcomes in Stage IV Disease

December 5th 2023

In this final episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, shed light on clinical outcomes following surgery of the primary tumor in patients with stage IV breast cancer.

Assessing the Promise of AI in Oncology: Potential Role in Cancer Screening, Diagnosis, Staging

December 4th 2023

In this sixth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss potential opportunities to leverage artificial intelligence tools in cancer screening, diagnosis, staging, and prognosis.

Dr Gallagher on Unmet Needs With ADCs in Breast Cancer

December 1st 2023

Christopher M. Gallagher, MD, discusses unmet needs surrounding the use of antibody-drug conjugates, as well as questions remaining with other approved agents in breast cancer.

Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care

November 27th 2023

Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.

Assessing the Promise of AI in Oncology: Call for Evidence

November 27th 2023

In this fifth episode of OncChats: Assessing the Promise of AI in Oncology, Toufic A. Kachaamy, MD, and Douglas Flora, MD, LSSBB, FACCC, discuss the need for evidence to support the utilization of different artificial intelligence tools in healthcare.

Taletrectinib Under NMPA Review in China for Advanced or Metastatic ROS1+ NSCLC

November 22nd 2023

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of the next-generation ROS1 TKI taletrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer with prior exposure to a ROS1 TKI.

Bayer Recalls Oral Larotrectinib Solution Because of Microbial Contamination

November 22nd 2023

Bayer has voluntarily recalled 1 lot of the larotrectinib 20 mg/mL oral solution that is packaged in 100-mL glass bottles because of the presence of Penicillium brevicompactum contamination that was observed during ongoing, routine stability testing.

Dr Tan on the Use of the Signatera™ Assay in RCC

November 22nd 2023

Alan Tan, MD, discusses the ongoing potential utility of circulating tumor DNA in patients with renal cell carcinoma and highlights how this approach is being used in his own practice.

FDA Approves Companion Diagnostic for Capivasertib Plus Fulvestrant in Advanced HR+/HER2–Breast Cancer

November 21st 2023

The FDA has approved the FoundationOne® CDx for use as a companion diagnostic to identify patients with advanced hormone receptor–positive, HER2-negative advanced breast cancer who may be eligible for treatment with the combination of capivasertib and fulvestrant.